Blueprint Medicines Corp - Company Profile
Powered by
All the data and insights you need on Blueprint Medicines Corp in one report.
- Save hours of research time and resources with
our up-to-date Blueprint Medicines Corp Strategy Report
- Understand Blueprint Medicines Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Blueprint Medicines Corp (Blueprint Medicines) is a precision therapy company that invented medicines for the treatment of cancer and blood disorders. The company product pipeline includes AYVAKIT (avapritinib) medicine to treat gastrointestinal stromal tumor (GIST) and GAVRETO (pralsetinib) for non-small cell lung cancer in adults, BLU-263 targeting indolent systemic mastocytosis. Blueprint Medicines also offers GAVRETO, BLU-701, BLU-945, BLU-451, BLU-222 and BLU-852. The company is advancing pralsetinib inhibitor against RET (Ret Proto-Oncogene) modified medullary thyroid carcinoma and other solid tumors and avapritinib to treat advanced systemic mastocytosis. The company utilizes its discovery which combines bioinformatics and drug design capabilities to develop its medicines. Blueprint Medicines is headquartered in Cambridge, Massachusetts, the US.
Blueprint Medicines Corp premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Pipeline | AYVAKIT |
AYVAKIT (avapritinib) - Advanced Systemic Mastocytosis, Indolent SM | GAVRETO |
Elenestinib (BLU-263) (KIT)- Indolent SM | |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In January, the company and VantAI entered into an agreement to improve novel targeted protein degrader therapies. |
2023 | Regulatory Approval | In December, the company secured approval from the European Commission for AYVAKYT for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms. |
2023 | Regulatory Approval | In January, the company announced that FDA approved the company's supplemental new drug application for AYVAKIT (avapritinib) for the treatment of adults with indolent systemic mastocytosis. |
Competitor Comparison
Key Parameters | Blueprint Medicines Corp | Pfizer Inc | Bayer AG | Novartis AG | AstraZeneca Plc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | Germany | Switzerland | United Kingdom |
City | Cambridge | New York | Leverkusen | Basel | Cambridge |
State/Province | Massachusetts | New York | Nordrhein-Westfalen | - | England |
No. of Employees | 655 | 88,000 | 99,723 | 76,057 | 89,900 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Jeffrey W. Albers | Chairman | Executive Board | 2022 | 51 |
Kate Haviland | Chief Executive Officer; Director; President | Executive Board | 2022 | 47 |
Mike Landsittel | Chief Financial Officer | Senior Management | 2019 | 51 |
Christina Rossi | Chief Operating Officer | Senior Management | 2022 | 47 |
Debra Durso-Bumpus | Chief People Officer | Senior Management | 2020 | 53 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer